Xanastim

Xanastim operates at the intersection of neurotechnology, medical devices, digital health, and wellness, focusing on non-invasive auricular vagus nerve stimulation rather than implantable neuromodulation. Its differentiation is architectural: BODUS combines a customized or wearable ear-based stimulator, physiological sensing, a mobile control layer, and cloud-based treatment management in one system. The company also describes multisite stimulation, personalized treatment dosing, and heart-rate-variability monitoring as parts of its approach. This gives Xanastim a broader product scope than a standalone stimulation device, but it also places the business in a demanding category where clinical validation, regulatory clearance, reimbursement, and repeatable treatment outcomes influence adoption. Relative to its disclosed scale, the company remains an early-stage specialist: it reports 1–10 employees, four financings, and $1.32 million in total funding. Its Swiss-Spanish identity and focus on personalized, wearable neuromodulation are clear differentiators, while market traction and competitive share remain unverified.

Xanastim’s trajectory shows a transition from early research funding toward an integrated neurostimulation platform. The company was founded in 2016 and received a $59,056 grant in 2017, followed by a $295,607 Pre Seed round in 2019 and two Seed rounds of $453,425 in 2020 and $511,960 in 2021. These financings total $1,320,048 and indicate that the principal capital-building phase occurred between 2017 and 2021. Product development has centered on BODUS, a portable auricular vagus nerve stimulation system supported by a smartphone application, physiological monitoring, and cloud-based personalization. A patent publication dated Dec 28, 2023 covering bilateral auricular vagus nerve stimulation marks a later intellectual-property milestone. Three current positions are identified, held by the founding leadership team. The resulting profile is one of continued technical specialization with limited publicly evidenced scaling. Future growth would likely depend on clinical adoption, regulatory progress, manufacturing execution, and converting the platform’s multi-indication pipeline into validated and commercially repeatable use cases.